In collaboration with leading cancer centers, research results to be presented from 11 studies across six solid tumor types demonstrating Caris’ impact on precision medicine
IRVING, Texas, January 17, 2024 – Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 11 studies across six solid tumor types at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco. The findings demonstrate the power of Caris’ comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan and response to treatment.
“We are proud to again present a wide array of precision oncology research at this year’s ASCO GI. The findings represent important observations in a variety of GI tumors, including potential new biomarkers for EGFRi efficacy in metastatic colorectal cancer, age stratification in cholangiocarcinoma, and a survey of immunogenic tumor neoantigens in colorectal, biliary, and pancreatic cancers,” said Chadi Nabhan, MD, MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “We are confident that Caris’ powerful comprehensive molecular profiling, the matched clinical outcomes data, and the in-depth collaboration with our POA member institutions and investigators will lead to novel insights into cancer biology, new targeted therapies, and ultimately improved outcomes for all cancer patients.”
Posters from Caris include:
Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma (Merit Award)
Poster Session B | Poster F3 | Abstract 536
January 19; 12:30 – 2:00 PM PST & 5:00 – 6:00 PM PST
APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi)
Poster Session C | Poster D19 | Abstract 56
January 20; 6:30 – 7:55 AM PST & 11:30 AM – 1:00 PM PST
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness
Poster Session C | Poster M11 | Abstract 203
January 20; 6:30 – 7:55 AM PST & 11:30 AM – 1:00 PM PST
Additional Presentations Reveal the Power of Comprehensive Molecular Profiling for Biological Discovery
Poster and abstract summaries highlighting all the Caris research presented at ASCO GI 2024 will be available onsite at Caris’ booth (#56). The full abstracts will be available through Caris’ website beginning on January 17.
The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
About Caris Life Sciences
Caris Life Sciences® is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com.